ImmuCell Announces Product Sales Growth and Profit

PORTLAND, ME -- (Marketwire) -- 05/14/12 -- ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month period ended March 31, 2012.

During the three-month period ended March 31, 2012, product sales increased by 10%, or $161,000, to $1,717,000 in comparison to the same period in 2011. During the twelve-month period ended March 31, 2012, product sales increased by 14%, or $642,000, to $5,273,000 in comparison to the same period in 2011.

"A 13% increase in sales of our lead product, First Defense®, during the first three months of 2012 over the same period in 2011, demonstrates a solid return on our increased investment in sales and marketing," commented Michael F. Brigham, President and CEO. "Based primarily on increased gross margin from sales of First Defense® and the anticipated reduction in product development expenditures, we returned to profitable operations for the first time since the first quarter of 2008."

Income before income taxes was $271,000 during the three-month period ended March 31, 2012, in contrast to a loss before income taxes of ($31,000) during the same period in 2011. Net income was $155,000, or $0.05 per share, during the three-month period ended March 31, 2012, in contrast to a net loss of ($23,000), or ($0.01) per share, during the same period in 2011.

Cash, cash equivalents and short-term investments increased by 2%, or $95,000, to $5,054,000 at March 31, 2012 as compared to $4,960,000 at December 31, 2011. Stockholders' equity increased by 3%, or $227,000, to $9,247,000 at March 31, 2012 as compared to $9,020,000 at December 31, 2011. The Company had 3,019,000 shares of common stock outstanding as of March 31, 2012.

                                                            (Unaudited)
                                                        Three-Month Periods
                                                          Ended March 31,
                                                       --------------------
(In thousands, except per share amounts)                  2012       2011
                                                       ---------  ---------

Product sales                                          $   1,717  $   1,556
Costs of goods sold                                          705        687
                                                       ---------  ---------
  Gross margin                                             1,012        869

Product development expenses                                 248        472
Sales, marketing and administrative expenses                 483        414
                                                       ---------  ---------
  Other operating expenses                                   731        886
                                                       ---------  ---------

NET OPERATING INCOME (LOSS)                                  281        (17)

Other (expenses) revenues, net                               (10)       (14)
                                                       ---------  ---------

INCOME (LOSS) BEFORE INCOME TAXES                            271        (31)

Income tax expense (benefit)                                 116         (8)
                                                       ---------  ---------

NET INCOME (LOSS)                                      $     155  $     (23)
                                                       =========  =========

Weighted average common shares outstanding:
  Basic                                                    3,016      2,974
  Diluted                                                  3,103      2,974

NET INCOME (LOSS) PER SHARE:
  Basic                                                $    0.05  $   (0.01)
  Diluted                                              $    0.05  $   (0.01)



                                               (Unaudited)
                                               At March 31,  At December 31,
(In thousands)                                     2012            2011
                                             --------------- ---------------

Cash, cash equivalents and short-term
 investments                                 $         5,054 $         4,960
Total assets                                          11,171          10,991
Net working capital                                    6,780           6,516
Stockholders' equity                         $         9,247 $         9,020

About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).

Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here